Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jan;84(2):170–178. doi: 10.1054/bjoc.2000.1572

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

P A Vasey 1, R Atkinson 2, R Coleman 3, M Crawford 4, M Cruickshank 5, P Eggleton 6,1, D Fleming 1, J Graham 7, D Parkin 5, J Paul 1, N S Reed 1, S B Kaye 1; on behalf of the Scottish Gynaecological Cancer Trials Group
PMCID: PMC2363708  PMID: 11161372

Abstract

A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic–IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.). 139 eligible patients (Pts) (median age 56 years, range 28–85) were given a total of 750 cycles of chemotherapy in 5 cohorts: Co1, 32 pts, 169 cycles (C at AUC 5 + D 60 mg/m2); Co2, 22 pts, 122 cycles (5 + 75), Co3, 29 pts, 156 cycles (6 + 75), Co4, 27 pts, 146 cycles (7 + 75), Co5, 30 pts, 157 cycles (6 + 85). 110 patients (79%) completed 6 cycles; 17 (12%) stopped due to toxicity. 104 patients (75%) had CTC grade IV neutropenia, and 5 patients (4%) had this associated with fever. There were 2 probable treatment-related deaths. Only 8 patients (6%) experienced grade II–III neurotoxicity (all sensory; no motor > grade I). The maximum tolerated dose was reached in cohorts 4 and 5, and the dose limiting toxicities were myelosuppression and diarrhoea. The overall response rate for the study was 66% (49/74); CA125 response was 75% (70/93). Median progression-free survival was 16.6 months (95% CI 13.3–19.1). Recommended doses are carboplatin AUC 5 (via51 Cr EDTA) or AUC 6 (if calculated) plus docetaxel 75 mg/m2. A randomized trial comparing this regimen with carboplatin-paclitaxel has just completed recruitment. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: ovarian carcinoma, chemotherapy, docetaxel, carboplatin

Full Text

The Full Text of this article is available as a PDF (112.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. A'Hern R. P., Gore M. E. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol. 1995 Mar;13(3):726–732. doi: 10.1200/JCO.1995.13.3.726. [DOI] [PubMed] [Google Scholar]
  2. Aabo K., Adams M., Adnitt P., Alberts D. S., Athanazziou A., Barley V., Bell D. R., Bianchi U., Bolis G., Brady M. F. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer. 1998 Dec;78(11):1479–1487. doi: 10.1038/bjc.1998.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bolis G., Scarfone G., Zanaboni F., Villa A., Presti M., Melpignano M., Ferraris C., Tateo S., Guarnerio P., Gentile A. A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Eur J Cancer. 1997 Apr;33(4):592–595. doi: 10.1016/s0959-8049(96)00495-9. [DOI] [PubMed] [Google Scholar]
  4. Bookman M. A., McGuire W. P., 3rd, Kilpatrick D., Keenan E., Hogan W. M., Johnson S. W., O'Dwyer P., Rowinsky E., Gallion H. H., Ozols R. F. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol. 1996 Jun;14(6):1895–1902. doi: 10.1200/JCO.1996.14.6.1895. [DOI] [PubMed] [Google Scholar]
  5. Brown R., Hirst G. L., Gallagher W. M., McIlwrath A. J., Margison G. P., van der Zee A. G., Anthoney D. A. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 1997 Jul 3;15(1):45–52. doi: 10.1038/sj.onc.1201167. [DOI] [PubMed] [Google Scholar]
  6. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  7. Cassidy J., Paul J., Soukop M., Habeshaw T., Reed N. S., Parkin D., Kaye S. B. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol. 1998;41(2):161–166. doi: 10.1007/s002800050723. [DOI] [PubMed] [Google Scholar]
  8. Chantler C., Garnett E. S., Parsons V., Veall N. Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci. 1969 Aug;37(1):169–180. [PubMed] [Google Scholar]
  9. Chen X. Q., Stroun M., Magnenat J. L., Nicod L. P., Kurt A. M., Lyautey J., Lederrey C., Anker P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996 Sep;2(9):1033–1035. doi: 10.1038/nm0996-1033. [DOI] [PubMed] [Google Scholar]
  10. Hilkens P. H., Pronk L. C., Verweij J., Vecht C. J., van Putten W. L., van den Bent M. J. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer. 1997;75(3):417–422. doi: 10.1038/bjc.1997.68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hilkens P. H., Verweij J., Stoter G., Vecht C. J., van Putten W. L., van den Bent M. J. Peripheral neurotoxicity induced by docetaxel. Neurology. 1996 Jan;46(1):104–108. doi: 10.1212/wnl.46.1.104. [DOI] [PubMed] [Google Scholar]
  12. Hill M., Macfarlane V., Moore J., Gore M. E. Taxane/platinum/anthracycline combination therapy in advanced epithelial ovarian cancer. Semin Oncol. 1997 Feb;24(1 Suppl 2):S2–34-S2-37. [PubMed] [Google Scholar]
  13. Huizing M. T., van Warmerdam L. J., Rosing H., Schaefers M. C., Lai A., Helmerhorst T. J., Veenhof C. H., Birkhofer M. J., Rodenhuis S., Beijnen J. H. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol. 1997 May;15(5):1953–1964. doi: 10.1200/JCO.1997.15.5.1953. [DOI] [PubMed] [Google Scholar]
  14. Kaye S. B., Piccart M., Aapro M., Francis P., Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. Eur J Cancer. 1997 Nov;33(13):2167–2170. doi: 10.1016/s0959-8049(97)00363-8. [DOI] [PubMed] [Google Scholar]
  15. Kunitoh H., Saijo N., Furuse K., Noda K., Ogawa M. Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion. Br J Cancer. 1998 May;77(10):1686–1688. doi: 10.1038/bjc.1998.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lhommé C., Kerbrat P., Lejeune C., Guastalla J. P., Fumoleau P., Goupil A., Héron J. F., Cassin M. A., Pruvot I., Soares J. A. Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study. Semin Oncol. 1996 Oct;23(5 Suppl 12):48–54. [PubMed] [Google Scholar]
  17. McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. Y., Clarke-Pearson D. L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1–6. doi: 10.1056/NEJM199601043340101. [DOI] [PubMed] [Google Scholar]
  18. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  19. Nawroz H., Koch W., Anker P., Stroun M., Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996 Sep;2(9):1035–1037. doi: 10.1038/nm0996-1035. [DOI] [PubMed] [Google Scholar]
  20. New P. Z., Jackson C. E., Rinaldi D., Burris H., Barohn R. J. Peripheral neuropathy secondary to docetaxel (Taxotere) Neurology. 1996 Jan;46(1):108–111. doi: 10.1212/wnl.46.1.108. [DOI] [PubMed] [Google Scholar]
  21. Omura G. A., Brady M. F., Homesley H. D., Yordan E., Major F. J., Buchsbaum H. J., Park R. C. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991 Jul;9(7):1138–1150. doi: 10.1200/JCO.1991.9.7.1138. [DOI] [PubMed] [Google Scholar]
  22. Piccart M. J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., Stuart G., Kaye S., Vergote I., Blom R. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000 May 3;92(9):699–708. doi: 10.1093/jnci/92.9.699. [DOI] [PubMed] [Google Scholar]
  23. Pitei D. L., Watkins P. J., Stevens M. J., Edmonds M. E. The value of the Neurometer in assessing diabetic neuropathy by measurement of the current perception threshold. Diabet Med. 1994 Nov;11(9):872–876. doi: 10.1111/j.1464-5491.1994.tb00371.x. [DOI] [PubMed] [Google Scholar]
  24. Righetti S. C., Della Torre G., Pilotti S., Ménard S., Ottone F., Colnaghi M. I., Pierotti M. A., Lavarino C., Cornarotti M., Oriana S. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996 Feb 15;56(4):689–693. [PubMed] [Google Scholar]
  25. Rowinsky E. K., Chaudhry V., Cornblath D. R., Donehower R. C. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr. 1993;(15):107–115. [PubMed] [Google Scholar]
  26. Rustin G. J., Nelstrop A. E., McClean P., Brady M. F., McGuire W. P., Hoskins W. J., Mitchell H., Lambert H. E. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996 May;14(5):1545–1551. doi: 10.1200/JCO.1996.14.5.1545. [DOI] [PubMed] [Google Scholar]
  27. Siddiqui N., Boddy A. V., Thomas H. D., Bailey N. P., Robson L., Lind M. J., Calvert A. H. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br J Cancer. 1997;75(2):287–294. doi: 10.1038/bjc.1997.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Strathdee G., MacKean M. J., Illand M., Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 1999 Apr 8;18(14):2335–2341. doi: 10.1038/sj.onc.1202540. [DOI] [PubMed] [Google Scholar]
  29. Valero V. Treatment of patients resistant to paclitaxel therapy. Anticancer Drugs. 1996 Aug;7 (Suppl 2):17–19. [PubMed] [Google Scholar]
  30. Vasey P. A., Paul J., Birt A., Junor E. J., Reed N. S., Symonds R. P., Atkinson R., Graham J., Crawford S. M., Coleman R. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol. 1999 Jul;17(7):2069–2080. doi: 10.1200/JCO.1999.17.7.2069. [DOI] [PubMed] [Google Scholar]
  31. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 1993 Jan 15;71(2 Suppl):517–523. doi: 10.1002/cncr.2820710205. [DOI] [PubMed] [Google Scholar]
  32. du Bois A., Lück H. J., Bauknecht T., Möbus V., Bochtler H., Diergarten K., Meerpohl H. G. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Ann Oncol. 1997 Apr;8(4):355–361. doi: 10.1023/a:1008267419453. [DOI] [PubMed] [Google Scholar]
  33. ten Bokkel Huinink W. W., van Warmerdam L. J., Helmerhorst T. J., Schaefers M. C., Beijnen J. H., Rodenhuis S. Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. Ann Oncol. 1997 Apr;8(4):351–354. doi: 10.1023/a:1008219618331. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES